多组学助力紫杉醇合成生物学研究  

Recent progress of paclitaxel biosynthesis aided by multi-omics

作　　者：吴迎梅 廖庆刚 尚轶 龚振平[3] 苟君波 Wu Ying-Mei;Liao Qing-Gang;Shang Yi;Gong Zhen-Ping;Gou Jun-Bo(School of Life Science,The AGISCAAS-YNNU Joint Academy of Potato Sciences,Yunnan Normal University,Yunnan Key Laboratory of Potato Biology,Kunming 650500,China;Shenzhen Branch,Guangdong Laboratory for Lingnan Modern Agriculture,Shenzhen Key Laboratory of Agricultural Synthetic Biology,Genome Analysis Laboratory of the Ministry of Agriculture and Rural Affairs,Agricultural Genomics Institute at Shenzhen,Chinese Academy of Agricultural Sciences,Shenzhen,Guangdong 518124,China;Tangshan Academy of Agricultural Sciences,Tangshan,Hebei 063001,China)

机构地区：[1]云南师范大学生命科学学院,马铃薯科学研究院,云南省马铃薯生物学重点实验室,昆明650500 [2]中国农业科学院农业基因组研究所,农业部基因组分析重点实验室,广东省岭南现代农业实验室,广东深圳518124 [3]唐山市农业科学研究院,河北唐山063001

出　　处：《植物科学学报》2022年第6期853-866,共14页Plant Science Journal

基　　金：国家自然科学基金(32000236);国家重点研发项目(2019YFA09006200)。

摘　　要：紫杉醇是高效的天然抗癌产物,广泛用于多种癌症的临床治疗。目前紫杉醇的生产主要是从红豆杉属(Taxus)植物中提取天然前体(如巴卡亭Ⅲ)然后再化学合成。受制于红豆杉植物资源,导致制药成本高。合成生物学的兴起为紫杉醇原料药的获取提供了新途径,但紫杉醇合成生物学的研究还有待推进。近年来,多组学被逐步应用到紫杉醇的合成生物学研究中。本文综述了多组学助力紫杉醇合成通路基因、调控基因和异源合成研究的最新进展,为紫杉醇的合成生物学研究提供了新的见解。Taxol(generic name paclitaxel) is a highly effective anti-cancer agent widely used in the clinical treatment of various cancers. At present, the production of paclitaxel is primarily based on artificial semi-synthesis from extracted intermediates(such as baccatin Ⅲ). This commercial method still relies on Taxus plant resources, resulting in high medical costs. The rise of synthetic biology provides a novel approach to acquire sufficient paclitaxel, but research on its biosynthesis is yet to be advanced. Recently, multi-omics approaches have been applied in biosynthesis research on paclitaxel. In the present paper, we review recent progress on the biosynthesis, regulation, and heterologous production of paclitaxel aided by multi-omics, providing new insights into paclitaxel biosynthesis.

关 键 词：红豆杉 紫杉醇 多组学 合成生物学 

分 类 号：TQ463[化学工程—制药化工]